Evidence map›Paper›PMID 19105204›Full record

ReviewAmerican journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics2009

The FMR1 gene and fragile X-associated tremor/ataxia syndrome.

J R Brouwer, R Willemsen, B A Oostra

Open access · greenAbstract readReview
In one paragraph

Review in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 113 citations in OpenAlex.

  1. Fragile X Syndrome in Adulthood: A Study of Electronic Health Records.American journal on intellectual and developmental disabilities · 2026
    Article
  2. Review
  3. Article
  4. Neurodegeneration of White and Gray Matter in the Hippocampus with FXTAS.International journal of molecular sciences · 2023
    Article
  5. Review
  6. Neuropathology ofBrain communications · 2021
    Article
  7. Review
  8. Data-driven phenotype discovery ofScience advances · 2019
    Article
  9. Repeat-associated non-AUG (RAN) translation: insights from pathology.Laboratory investigation; a journal of technical methods and pathology · 2019
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. mTOR, a Potential Target to Treat Autism Spectrum Disorder.CNS & neurological disorders drug targets · 2016
    Review
  15. Article
  16. A high resolution map of mammalian X chromosome fragile regions assessed by large-scale comparative genomics.Mammalian genome : official journal of the International Mammalian Genome Society · 2014
    Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

J R BrouwerDepartment of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands.
R Willemsen
B A Oostra
Erasmus MC · NLErasmus University Rotterdam · NL

Funding

Mouse Models of FXTAS: Defining Critical Periods and Molecular TargetsRL1NS062411 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERMAN, ROBERT F · 2007 to 2011
$4.2M
Fragile X Related Genes Mental Retardiation/DevelopmentR01HD038038 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI NELSON, DAVID LOREN · 1999 to 2009
$3.1M
Neuro Therapeutics Research InstituteUL1RR024922 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2007 to 2007
$807k
NCRR NIH HHS UL1 RR024922NICHD NIH HHS R01 HD038038NICHD NIH HHS R01 HD38038NINDS NIH HHS RL1 NS062411
6 · The paper itself

Abstract

The CGG-repeat present in the 5'UTR of the FMR1 gene is unstable upon transmission to the next generation. The repeat is up to 55 CGGs long in the normal population. In fragile X patients, a repeat length exceeding 200 CGGs (full mutation: FM) generally leads to methylation of the repeat and the promoter region, which is accompanied by silencing of the FMR1 gene. The gene product FMRP is involved in regulation of transport and translation of certain mRNA in the dendrite, thereby affecting synaptic plasticity. This is central to learning and memory processes. The absence of FMRP seen in FM is the cause of the mental retardation seen in fragile X patients. The premutation (PM) is defined as 55-200 CGGs. Female PM carriers are at risk of developing primary ovarian insufficiency. Recently it was discovered that elderly PM carriers might develop a progressive neurodegenerative disorder called fragile X-associated tremor/ataxia syndrome. Although arising from the mutations in the same gene, distinct mechanisms lead to fragile X syndrome (absence of FMRP) and FXTAS (toxic RNA gain of function). The pathogenic mechanisms thought to underlie these disorders are discussed, with a specific emphasis on FXTAS. This review gives insight on the implications of all possible repeat length categories seen in fragile X families.

Indexed as

AnimalsAtaxiaDisease Models, AnimalFemaleFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeHumansMaleMiceSyndromeTremorTrinucleotide RepeatsFragile X Messenger Ribonucleoprotein 1

Identifiers

PMID19105204
PMCPMC4320942
OpenAlexW2059502738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.